Status:
UNKNOWN
Concentrations of Formoterol in Blood and Urine
Lead Sponsor:
Bispebjerg Hospital
Collaborating Sponsors:
Hormone Laboratory, Aker University Hospital, Oslo, Norway
Conditions:
Asthma
Eligibility:
MALE
18-45 years
Phase:
PHASE4
Brief Summary
The purpose of the study is to assess the blood and urine concentrations of inhaled formoterol.
Detailed Description
The purpose of the study is to assess the serum and urine concentrations after inhalation of 18 microgram formoterol as one dose. Furthermore to investigate the serum and urine concentrations of inha...
Eligibility Criteria
Inclusion
- Physician-diagnosed asthma with positive reversibility or challenge test.
- Informed consent.
- Age between 18-45 years.
- Sex: male.
- Asthma classified as mild to moderate according to GINA guidelines.
- Used beta-2-agonist in minimum 12 months.
Exclusion
- Smokers or ex-smokers with a smoking history of 10 pack years or more.
- Respiratory tract infections within the last 2 weeks prior to study day.
- Subjects with other chronic diseases than asthma and allergy.
- Allergy towards the study medicine.
- Use of beta-2-agonist 10 days prior to study day.
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2010
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00914654
Start Date
July 1 2009
End Date
December 1 2010
Last Update
June 5 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bispebjerg Hospital, Respiratory Research Unit
København NV, Denmark, DK-2400